$PFE 0.52 Developing

Notable posts

• @wallstengine neutral 34 eng

  Pfizer $PFE said sigvotatug vedotin failed to significantly improve overall survival vs. docetaxel in advanced non-small cell lung cancer. Pfizer acquired the antibody-drug conjugate through its $43B Seagen deal. The company will continue developing the drug, including a late-stage combo study with Merck’s Keytruda in first-line lung cancer.

  view on X →
• @faststocknewss neutral 9 eng

  Pfizer $PFE reaffirms FY2026 guidance following a CFO transition announcement, per an SEC filing.

  view on X →
• @tenet_research neutral 25 eng

  Tenet Market Wake-Up Summary 📷📷 June.18.26 $SPX $AAPL $INTC $AVGO $OKLO $LEU $META $TSLA $NOK $RUM $UUUU $QBTS $ONDS $ZETA $PFE $SPCX $TSEM $MRVL $SWBI $ACN $KR $ALB $ENPH $QURE $CEG $TLN $CURB $ENGN $INTU $CAST $LNKS $LPA $NVCR $LEGN @ripster47 | @tenet_research | @TenetCharts

  view on X →
• @tenet_research neutral 25 eng

  Tenet Market Wake-Up Summary 📷📷 June.08.26 $SPX $AAPL $NVDA $AMZN $BA $MA $V $UAL $AAL $DAL $JBLU $NOK $ABAT $UBER $NBIS $SPOT $CRWV $PFE $FCEL $CPB $ALOT $BIIB $CROX $CTSH $WRB $CBRS $ALL $CSR $GMHS $TNGX $MRVL $BW @ripster47 | @TENETTRADEGROUP | @TenetCharts https://t.co/zKMUGXnV7I

  view on X →